The trading price of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) floating lower at last check on Monday, Feb 22, closing at $15.95, -2.63% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $15.42 and $15.95. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 0. In examining the 52-week price action we see that the stock hit a 52-week high of $20.5 and a 52-week low of $9.83. Over the past month, the stock has gained 9.25% in value.
Aurinia Pharmaceuticals Inc., whose market valuation is $2.01 Billion at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.14 per share this quarter, however they have predicted annual earnings per share of -$1.01 for 2021 and -$0.55 for 2022. It means analysts are expecting annual earnings per share growth of 0.53% this year and -0.46% next year.
On the technical side, indicators suggest AUPH has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 50% Buy.
An evaluation of the daily trading volume of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) indicates that the 3-month average is 4.05 Million. However, this figure has declined over the past 10 days to an average of 2.72 Million.
Currently, records show that 126.25 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 9.77% of outstanding shares, whereas institutions hold 55.87%. The stats also highlight that short interest as of January 28, 2021, stood at 5.4 Million shares, resulting in a short ratio of 0.87 at that time. From this, we can conclude that short interest is 4.26% of the company’s total outstanding shares. It is noteworthy that short shares in January were up slightly from the previous month’s figure, which was 5.12 Million. However, since the stock’s price has seen +15.33% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.